A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Rochester, Minn., Jacksonville, Fla., Phoenix/Scottsdale, Ariz.
Open for Enrollment
Why is this study being done?
This study is to evaluate the efficacy and safety of simtuzumab (GS-6624) in adults with idiopathic pulmonary fibrosis.
Who can I contact for additional information about this study?
Rochester: Suson Walsh 507-293-0637
Scottsdale: Michaele Menghini 480-301-6651
Jacksonville: Pamela Long 904-953-7719